Mycophenolate mofetil in primary glomerulopathies

Kidney International

Volumn 73, Issue 2, 2008, Pages 154-162

  Sepe, V ^a,b   Libetta, C ^a,b   Giuliano, M G ^a,b   Adamo, G ^a,b   Dal Canton, A ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Focal segmental glomerulosclerosis; Idiopathic membranous nephropathy; IgA nephropathy; Minimal change nephropathy; Mycophenolate mofetil; Steroids

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ENALAPRIL; LOSARTAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; STEROID;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; DRUG MECHANISM; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GLOMERULOPATHY; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NAUSEA; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VOMITING;

EID: 37549015225     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002653     Document Type: Review

References (45)

1. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanism of action. Immunopharmacology 2000; 47: 85-118.
2. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346.
3. Cross J, Jayne D. Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol 2005; 19: 795-798.
4. Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005; 80(2 Suppl): S191-S200.
5. Jayne D. Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens 1999; 8: 563-567.
6. Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001; 10: 203-208.
7. Gelber AG, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000; 27: 1542-1545.
8. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long term efficacy and safety. J Am Acad Dermatol 1987; 17: 962-971.
9. Gosio B. Sperimentate su culture pure di bacilli del carbonchio dimonstrarono notevole potere antisettico. C R Acad Med Torino 1893; 61: 484.
10. Alsberg CL, Black OF Contributions to the study of maize deterioration, p. 7-48. US Dept.of Agr. Bur. Plant Ind. Bull. 270 1913.
11. Birkinshaw JH, Raistrick H, Ross DJ. Studies in the biochemistry of microorganisms 86. The molecular constitution of mycophenolic acid, a metabolic product of Penicillium Brevi-compactum Dierckx. Part III. Further observations on the structural formula for mycophenolic acid. Biochem J 1952; 50: 630-634.
12. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113: 515-524.
13. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286-27290.
14. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5-28.
15. Ji YS, Gu JJ, Makhov AM et al. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP. J Biol Chem 2006; 281: 206-212.
16. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994; 26: 3205-3210.
17. Byars NE. Effects of RS-5797-000 (mycophenolic acid) on the amounts of ATP and GTP in polymorphonuclear cells and in adherent and non-adherent human mononuclear cells. Research report (Study ID CL 6524); Syntex discovery research, Palo Alto, CA 1993.
18. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005;80(2 Suppl): S181-S190.
19. Patari-Sampo A, Ihalmo P, Holthofer H. Molecular basis of the glomerular filtration: nephrin and the emerging complex at the podocyte slit diaphragm. Ann Med 2006; 38: 483-492.
20. Nakhoul F, Ramadan R, Khankin E et al. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies. Am J Physiol Renal Physiol 2005; 289: F880-F890.
21. Bloudickova S, Rajnoch J, Lodererova A et al. Mycophenolate mofetil ameliorates accelerated progressive nephropathy in rat. Kidney Blood Press Res 2006; 29: 60-66.
22. Hauser IA, Renders L, Radeke HH et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999; 14: 58-63.
23. Rodriguez-Iturbe B, Quiroz Y, Shahkarami A et al. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int 2005; 68: 1041-1047.
24. Kramer S, Loof T, Martini S et al. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol 2005; 289: F359-F368.
25. Wang K, Zhang H, Li H et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 2004; 36: 2068-2070.
26. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US renal transplant Mycophenolate Mofetil study group. Transplantation 1995; 60: 225-232.
27. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
28. Mycophenolate Mofetil Renal Refractory Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722-729.
29. First MR. Renal function as a predictor of long-term graft survival in renal transplant patients. Nephrol Dial Transplant 2003; 18(Suppl 1): i3-i6.
30. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
31. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
32. Karim MY, Pisoni CN, Ferro L et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005; 44: 1317-1321.
33. Pisoni CN, Sanchez FJ, Karim Y et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047-1052.
34. Carruthers SG, Larochelle P, Haynes RB et al. Report of the Canadian hypertension society consensus conference: 1. Introduction. CMAJ 1993; 149: 289-293.
35. Mendizábal S, Zamora I, Berbel O et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005; 20: 914-919.
36. Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004; 19: 101-104.
37. Day CJ, Cockwell P, Lipkin GW et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17: 2011-2013.
38. Choi JM, Eustace JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098-1114.
39. Cattran DC, Wang MM, Appel G et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 6: 405-411.
40. Montané B, Abitbol C, Chandar J et al. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003; 18: 772-777.
41. Miller G, Zimmerman III R, Radhakrishnan J, Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000; 36: 250-256.
42. Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant 2003; 18: 1233-1234.
43. Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-1849.
44. Frisch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized trial. Nephrol Dial Transplant 2005; 20: 2139-2145.
45. Tang S, Leung JCK, Chan LYY et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802-812.